XTX Topco Ltd Sells 114,794 Shares of Generation Bio Co. (NASDAQ:GBIO)

XTX Topco Ltd trimmed its position in Generation Bio Co. (NASDAQ:GBIO) by 86.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 17,922 shares of the company’s stock after selling 114,794 shares during the period. XTX Topco Ltd’s holdings in Generation Bio were worth $44,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of GBIO. FMR LLC raised its position in Generation Bio by 0.3% in the third quarter. FMR LLC now owns 5,320,266 shares of the company’s stock valued at $13,141,000 after purchasing an additional 15,656 shares during the last quarter. Baker BROS. Advisors LP increased its stake in shares of Generation Bio by 61.1% in the third quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock valued at $4,804,000 after buying an additional 737,988 shares during the period. State Street Corp boosted its position in Generation Bio by 1.2% during the 3rd quarter. State Street Corp now owns 992,188 shares of the company’s stock worth $2,451,000 after buying an additional 11,669 shares during the period. Acadian Asset Management LLC grew its holdings in Generation Bio by 23.9% during the 2nd quarter. Acadian Asset Management LLC now owns 594,569 shares of the company’s stock worth $1,675,000 after acquiring an additional 114,734 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Generation Bio by 2.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock valued at $1,046,000 after acquiring an additional 8,692 shares during the period. Institutional investors and hedge funds own 95.22% of the company’s stock.

Wall Street Analyst Weigh In

GBIO has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Generation Bio in a report on Wednesday, October 23rd. Wedbush reaffirmed an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a report on Thursday, November 7th.

Generation Bio Stock Performance

Generation Bio stock opened at $1.19 on Monday. The firm has a market cap of $79.48 million, a price-to-earnings ratio of -0.54 and a beta of 2.66. Generation Bio Co. has a 52-week low of $0.75 and a 52-week high of $4.65. The firm has a 50 day moving average price of $1.75 and a two-hundred day moving average price of $2.35.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.